

# Yue Yang

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/979094/publications.pdf>

Version: 2024-02-01

102  
papers

2,958  
citations

346980

22  
h-index

223390

49  
g-index

113  
all docs

113  
docs citations

113  
times ranked

4750  
citing authors

#	ARTICLE	IF	CITATIONS
1	A Dual-Channel Intelligent Point-of-Care Testing System for Soluble Programmed Death-1 and Programmed Death-Ligand 1 Detection Based on Folding Paper-Based Immunosensors. <i>ACS Sensors</i> , 2022, 7, 584-592.	4.0	10
2	circ_0000567/miR-421<i>TMEM100</i> Axis Promotes the Migration and Invasion of Lung Adenocarcinoma and Is Associated with Prognosis. <i>Journal of Cancer</i> , 2022, 13, 1540-1552.	1.2	7
3	The COVID-19 vaccine: Attitudes and vaccination in patients with autoimmune inflammatory rheumatic diseases. <i>Rheumatology &amp; Autoimmunity</i> , 2022, 2, 82-91.	0.3	11
4	Percentage of Newly Proposed High-Grade Patterns Is Associated with Prognosis of Pathological T1-2N0M0 Lung Adenocarcinoma. <i>Annals of Surgical Oncology</i> , 2022, , 1.	0.7	3
5	Efficacy and safety of low-dose interleukin-2 in combination with methotrexate in patients with active rheumatoid arthritis: a randomized, double-blind, placebo-controlled phase 2 trial. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 67.	7.1	30
6	Intermittent chest tube clamping decreases chest tube duration time and drainage volume after lung cancer surgery in patients without air leak: an open-label, randomized controlled trial. <i>Translational Lung Cancer Research</i> , 2022, 11, 357-365.	1.3	1
7	MiR-224 promotes lymphatic metastasis by targeting ANGPTL1 in non-small-cell lung carcinoma. <i>Cancer Biomarkers</i> , 2022, 34, 431-441.	0.8	4
8	ASO Visual Abstract: Percentage of Newly Proposed High-Grade Patterns Is Associated With Prognosis of Pathologic T1-2N0M0 Lung Adenocarcinoma. <i>Annals of Surgical Oncology</i> , 2022, , 1.	0.7	0
9	PTPIP51 inhibits non-small-cell lung cancer by promoting PTEN-mediated EGFR degradation. <i>Life Sciences</i> , 2022, 297, 120293.	2.0	4
10	Multifunctional self-driven origami paper-based integrated microfluidic chip to detect CRP and PAB in whole blood. <i>Biosensors and Bioelectronics</i> , 2022, 208, 114225.	5.3	18
11	Neoadjuvant <sc>PD</sc>-1 inhibitor combines with chemotherapy versus neoadjuvant chemotherapy in resectable squamous cell carcinoma of the lung. <i>Thoracic Cancer</i> , 2022, 13, 442-452.	0.8	4
12	A Systematic Review of Swallowing Training Measures for Postoperative Oral Cancer Patients. <i>Dysphagia</i> , 2022, 37, 1839-1850.	1.0	4
13	Preoperative Patient and Lesion Features Are Valuable for Predicting the Prognosis of Resectable Peripheral Non-“Small Cell Lung Cancer. <i>Journal of Computer Assisted Tomography</i> , 2022, Publish Ahead of Print, .	0.5	0
14	An Evidence-Based Staging System for Mucosal Melanoma: A Proposal. <i>Annals of Surgical Oncology</i> , 2022, 29, 5221-5234.	0.7	15
15	ASO Visual Abstract: An Evidence-Based Staging System for Mucosal Melanoma: a Proposal. <i>Annals of Surgical Oncology</i> , 2022, , .	0.7	0
16	Analysis of overall survival (OS) and relapse-free-survival (RFS) in the phase 1b clinical trial of anti-“PD-1 ab (toripalimab) plus intralesional injection of OrienX010 in stage - melanoma with liver metastases.. <i>Journal of Clinical Oncology</i> , 2022, 40, 9551-9551.	0.8	2
17	Neoadjuvant Toripalimab plus chemotherapy in patients with stage IIB-IIIb NSCLC: A single-center, prospective, single-arm, phase 2 trial (Renaissance Study).. <i>Journal of Clinical Oncology</i> , 2022, 40, e21128-e21128.	0.8	0
18	Adjuvant temozolomide plus cisplatin versus high-dose interferon alpha-2b in resected mucosal melanoma: A randomized, multicenter, controlled, phase III trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, 9578-9578.	0.8	2

#	ARTICLE	IF	CITATIONS
19	Toripalimab plus axitinib versus toripalimab or axitinib alone in patients with treatment-naive unresectable or metastatic mucosal melanoma: Interim results from a randomized, controlled, phase II trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, 9512-9512.	0.8	2
20	Rapid Onset of Efficacy of Baricitinib in Chinese Patients with Moderate to Severe Rheumatoid Arthritis: Results from Study RA-BALANCE. <i>Advances in Therapy</i> , 2021, 38, 772-781.	1.3	5
21	Validation of the 8th Edition Nodal Staging and Proposal of New Nodal Categories for Future Editions of the TNM Classification of Non-Small Cell Lung Cancer. <i>Annals of Surgical Oncology</i> , 2021, 28, 4510-4516.	0.7	8
22	Patient-reported outcomes from a randomized, double-blind, placebo controlled, phase III study of baricitinib versus placebo in patients with moderately to severely active rheumatoid arthritis and an inadequate response to methotrexate therapy: results from the RA-BALANCE study. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2021, 13, 1759720X2110069.	1.2	3
23	An origami paper-based nanoformulated immunosensor detects picograms of VEGF-C per milliliter of blood. <i>Communications Biology</i> , 2021, 4, 121.	2.0	13
24	A pan-cancer single-cell transcriptional atlas of tumor infiltrating myeloid cells. <i>Cell</i> , 2021, 184, 792-809.e23.	13.5	563
25	Clinical recommendations for perioperative immunotherapy-induced adverse events in patients with non-small cell lung cancer. <i>Thoracic Cancer</i> , 2021, 12, 1469-1488.	0.8	7
26	Calcium channel $\beta_1$ subunit is a functional marker and therapeutic target for tumor-initiating cells in non-small cell lung cancer. <i>Cell Death and Disease</i> , 2021, 12, 257.	2.7	17
27	Small Cell Size Circulating Aneuploid Cells as a Biomarker of Prognosis in Resectable Non-Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 590952.	1.3	4
28	High-risk-pattern lung adenocarcinoma with epidermal growth factor receptor mutation is associated with distant metastasis risk and may benefit from adjuvant targeted therapy. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2021, 33, 395-401.	0.5	2
29	Osimertinib as neoadjuvant treatment for resectable stage II-IIIB EGFR mutant lung adenocarcinoma (NEOS).. <i>Journal of Clinical Oncology</i> , 2021, 39, 8524-8524.	0.8	6
30	Updated overall survival (OS) and exploratory analysis from the randomized, phase II EVAN study of erlotinib (E) versus vinorelbine plus cisplatin (NP) as adjuvant therapy in Chinese patients with stage IIIA EGFR+ NSCLC.. <i>Journal of Clinical Oncology</i> , 2021, 39, 8520-8520.	0.8	6
31	Different exposure duration of adjuvant icotinib in stage II-IIIa non-small cell lung cancer patients with positive EGFR mutation (ICOMPARE study): A randomized, open-label phase 2 study.. <i>Journal of Clinical Oncology</i> , 2021, 39, 8521-8521.	0.8	4
32	Major pathologic response assessment and clinical significance of metastatic lymph nodes after neoadjuvant therapy for non-small cell lung cancer. <i>Modern Pathology</i> , 2021, 34, 1990-1998.	2.9	13
33	HIF1A-AS2 induces osimertinib resistance in lung adenocarcinoma patients by regulating the miR-146b-5p/IL-6/STAT3 axis. <i>Molecular Therapy - Nucleic Acids</i> , 2021, 26, 613-624.	2.3	17
34	Aneuploid Circulating Tumor Cells as a Predictor of Response to Neoadjuvant Chemotherapy in Non-Small Cell Lung Cancer. <i>International Journal of General Medicine</i> , 2021, Volume 14, 6609-6620.	0.8	9
35	Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 141-149.	0.5	223
36	Improvement of the patient early mobilization protocol after oral and maxillofacial free flap reconstruction surgery. <i>Journal of Cranio-Maxillo-Facial Surgery</i> , 2020, 48, 43-48.	0.7	9

#	ARTICLE	IF	CITATIONS
37	Does neoadjuvant targeted therapy provide an opportunity for resectable EGFR-mutant lung cancer: a real-world retrospective study. <i>Journal of Thoracic Disease</i> , 2020, 12, 5324-5335.	0.6	11
38	Efficacy and Safety of Baricitinib in Chinese Rheumatoid Arthritis Patients and the Subgroup Analyses: Results from Study RA-BALANCE. <i>Rheumatology and Therapy</i> , 2020, 7, 851-866.	1.1	18
39	Low sample volume origami-paper-based graphene-modified aptasensors for label-free electrochemical detection of cancer biomarker-EGFR. <i>Microsystems and Nanoengineering</i> , 2020, 6, 32.	3.4	55
40	Recommended changes for the 8th edition of the TNM classification for lung cancer-the findings of a single-institution evaluation. <i>Annals of Translational Medicine</i> , 2020, 8, 123-123.	0.7	4
41	Tumor cell-intrinsic PD-1 receptor is a tumor suppressor and mediates resistance to PD-1 blockade therapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 6640-6650.	3.3	141
42	External validation of the eighth edition of the TNM classification for lung cancer in 3,611 surgically treated patients at a single institution. <i>Annals of Translational Medicine</i> , 2020, 8, 122-122.	0.7	2
43	Deep learning combined with radiomics may optimize the prediction in differentiating high-grade lung adenocarcinomas in ground glass opacity lesions on CT scans. <i>European Journal of Radiology</i> , 2020, 129, 109150.	1.2	24
44	Impact of Early Oral Feeding on Anastomotic Leakage Rate After Esophagectomy: A Systematic Review and Meta-analysis. <i>World Journal of Surgery</i> , 2020, 44, 2709-2718.	0.8	15
45	Efficacy and Safety of PD-1/PD-L1 Inhibitors Plus Chemotherapy Versus PD-1/PD-L1 Inhibitors in Advanced Non-Small Cell Lung Cancer: A Network Analysis of Randomized Controlled Trials. <i>Frontiers in Oncology</i> , 2020, 10, 574752.	1.3	11
46	Comprehensive analysis of T-cell receptor sequencing in resectable squamous cell lung cancer patients with neoadjuvant therapy of PD-1 inhibitor and chemotherapy.. <i>Journal of Clinical Oncology</i> , 2020, 38, e21012-e21012.	0.8	0
47	The prognostic analysis of lung cancer patients with occult malignant pleural disease at thoracotomy. <i>Translational Cancer Research</i> , 2020, 9, 1689-1697.	0.4	0
48	Baricitinib in patients with rheumatoid arthritis with inadequate response to methotrexate: results from a phase 3 study. <i>Clinical and Experimental Rheumatology</i> , 2020, 38, 732-741.	0.4	4
49	Distinct Molecular Mechanisms Analysis of Three Lung Cancer Subtypes Based on Gene Expression Profiles. <i>Journal of Computational Biology</i> , 2019, 26, 1140-1155.	0.8	5
50	Autoimmune diseases in China. <i>Advances in Immunology</i> , 2019, 144, 173-216.	1.1	12
51	Label-free microfluidic paper-based electrochemical aptasensor for ultrasensitive and simultaneous multiplexed detection of cancer biomarkers. <i>Biosensors and Bioelectronics</i> , 2019, 136, 84-90.	5.3	186
52	&lt;p&gt;Impact of preoperative exercise therapy on surgical outcomes in lung cancer patients with or without COPD: a systematic review and meta-analysis&lt;/p&gt;. <i>Cancer Management and Research</i> , 2019, Volume 11, 1765-1777.	0.9	32
53	Sequencing of the MHC region defines <i>HLA-DQA1</i> as the major genetic risk for seropositive rheumatoid arthritis in Han Chinese population. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 773-780.	0.5	27
54	Interleukin-2 Deficiency Associated with Renal Impairment in Systemic Lupus Erythematosus. <i>Journal of Interferon and Cytokine Research</i> , 2019, 39, 117-124.	0.5	26

#	ARTICLE	IF	CITATIONS
55	Expert consensus on multidisciplinary therapy of colorectal cancer with lung metastases (2019) Tj ETQq1 1 0.784314 rgBT /Qyerlock 10 6.9 69		
56	&lt;p&gt;Long-term survival of patients with locally advanced esophageal squamous cell carcinoma receiving esophagectomy following neoadjuvant chemotherapy: a cohort study&lt;/p&gt;. Cancer Management and Research, 2019, Volume 11, 1299-1308.	0.9	6
57	Shisa3 brakes resistance to EGFR-TKIs in lung adenocarcinoma by suppressing cancer stem cell properties. Journal of Experimental and Clinical Cancer Research, 2019, 38, 481.	3.5	26
58	Neoadjuvant Crizotinib in Resectable Locally Advanced Nonâ€“Small Cell Lung Cancer with ALKÂRearrangement. Journal of Thoracic Oncology, 2019, 14, 726-731.	0.5	67
59	Genomic sequencing and editing revealed the GRM8 signaling pathway as potential therapeutic targets of squamous cell lung cancer. Cancer Letters, 2019, 442, 53-67.	3.2	29
60	Should patients with stage IB non-small cell lung cancer receive adjuvant chemotherapy? A comparison of survival between the 8th and 7th editions of the AJCC TNM staging system for stage IB patients. Journal of Cancer Research and Clinical Oncology, 2019, 145, 463-469.	1.2	22
61	Five tumor-associated autoantibodies expression levels in serum predict lung cancer and associate with poor outcome. Translational Cancer Research, 2019, 8, 1364-1373.	0.4	7
62	Chemical proteomic profiling of protein<i>N</i>-homocysteinylation with a thioester probe. Chemical Science, 2018, 9, 2826-2830.	3.7	23
63	Left sleeve lobectomy versus left pneumonectomy for the management of patients with nonâ€“small cell lung cancer. Thoracic Cancer, 2018, 9, 348-352.	0.8	2
64	Monoclonal gammopathy in rheumatic diseases. Clinical Rheumatology, 2018, 37, 1751-1762.	1.0	22
65	Macrophage activation syndrome in systemic lupus erythematosus: a multicenter, case-control study in China. Clinical Rheumatology, 2018, 37, 93-100.	1.0	49
66	Novel <i>COL</i>5A1</i> mutation in a Chinese family with classic type of Ehlersâ€“Danlos syndrome. Journal of Dermatology, 2018, 45, 370-371.	0.6	1
67	Effect of low molecular weight heparin on venous thromboembolism disease in thoracotomy patients with cancer. Journal of Thoracic Disease, 2018, 10, 1850-1856.	0.6	11
68	BPI-9016M, a c-Met inhibitor, suppresses tumor cell growth, migration and invasion of lung adenocarcinoma via miR203-DKK1. Theranostics, 2018, 8, 5890-5902.	4.6	26
69	CD44 promotes cell proliferation in non-small cell lung cancer. Oncology Letters, 2018, 15, 5627-5633.	0.8	38
70	Investigation of C1-complex regions reveals new C1Q variants associated with protection from systemic lupus erythematosus, and affect its transcript abundance. Scientific Reports, 2018, 8, 8048.	1.6	8
71	Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung cancer (EVAN): a randomised, open-label, phase 2 trial. Lancet Respiratory Medicine,the, 2018, 6, 863-873.	5.2	224
72	Adjuvant chemotherapy may improve outcome of patients with non-small-cell lung cancer with metastasis of intrapulmonary lymph nodes after systematic dissection of N1 nodes. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2018, 30, 588-595.	0.7	4

#	ARTICLE	IF	CITATIONS
73	A consensus on liquid biopsy from the 2016 Chinese Lung Cancer Summit expert panel. <i>ESMO Open</i> , 2017, 2, e000174.	2.0	3
74	CMTM1_v17 is associated with chemotherapy resistance and poor prognosis in non-small cell lung cancer. <i>World Journal of Surgical Oncology</i> , 2017, 15, 34.	0.8	17
75	Prevention of Oral Candidiasis After Free Flap Surgery: Role of 3% Sodium Bicarbonate Saline in Oral Care. <i>Journal of Oral and Maxillofacial Surgery</i> , 2017, 75, 641-647.	0.5	1
76	Detection of circulating tumor cells in pulmonary venous blood for resectable non-small cell lung cancer. <i>Oncology Letters</i> , 2017, 15, 1103-1112.	0.8	10
77	LncRNA16 is a potential biomarker for diagnosis of early-stage lung cancer that promotes cell proliferation by regulating the cell cycle. <i>Oncotarget</i> , 2017, 8, 7867-7877.	0.8	28
78	iASPP facilitates tumor growth by promoting mTOR-dependent autophagy in human non-small-cell lung cancer. <i>Cell Death and Disease</i> , 2017, 8, e3150-e3150.	2.7	15
79	Impact of maximum standardized uptake value of non-small cell lung cancer on detecting lymph node involvement in potential stereotactic body radiotherapy candidates. <i>Journal of Thoracic Disease</i> , 2017, 9, 1023-1031.	0.6	8
80	Management of occult malignant pleural disease firstly detected at thoracotomy for non-small cell lung cancer patients. <i>Journal of Thoracic Disease</i> , 2017, 9, 3851-3858.	0.6	8
81	Intermittent chest tube clamping may shorten chest tube drainage and postoperative hospital stay after lung cancer surgery: a propensity score matching analysis. <i>Journal of Thoracic Disease</i> , 2017, 9, 5061-5067.	0.6	8
82	Impact of Omission of Intrapulmonary Lymph Node Retrieval on Outcome Evaluation of Lung Cancer Patients Without Lymph Node Metastasis: A Propensity Score Matching Analysis. <i>Clinical Lung Cancer</i> , 2017, 18, e411-e416.	1.1	17
83	Mediastinal micro-vessels clipping during lymph node dissection may contribute to reduce postoperative pleural drainage. <i>Journal of Thoracic Disease</i> , 2016, 8, 415-421.	0.6	7
84	Mediastinal lymphadenectomy fulfilling NCCN criteria may improve the outcome of clinical N0 and pathological N2 non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2016, 8, 342-349.	0.6	12
85	Upregulation of programmed cell death ligand 1 promotes resistance response in non-small cell lung cancer patients treated with neoadjuvant chemotherapy. <i>Cancer Science</i> , 2016, 107, 1563-1571.	1.7	147
86	A novel label-free microfluidic paper-based immunosensor for highly sensitive electrochemical detection of carcinoembryonic antigen. <i>Biosensors and Bioelectronics</i> , 2016, 83, 319-326.	5.3	129
87	Blockade of Notch3 inhibits the stem-like property and is associated with ALDH1A1 and CD44 via autophagy in non-small lung cancer. <i>International Journal of Oncology</i> , 2016, 48, 2349-2358.	1.4	35
88	An Investigation Into the Disease Profile and Healthcare Costs of Inpatients Treated at a Major Oral and Maxillofacial Surgical Center. <i>Journal of Craniofacial Surgery</i> , 2016, 27, e589-e595.	0.3	1
89	Combined analysis identifies six genes correlated with augmented malignancy from non-small cell to small cell lung cancer. <i>Tumor Biology</i> , 2016, 37, 2193-2207.	0.8	21
90	Induction of Patient-Derived Xenograft Formation and Clinical Significance of Programmed Cell Death Ligand 1 (PD-L1) in Lung Cancer Patients. <i>Medical Science Monitor</i> , 2016, 22, 4017-4025.	0.5	7

#	ARTICLE	IF	CITATIONS
91	ENTPD5 Induces Apoptosis in Lung Cancer Cells via Regulating Caspase 3 Expression. PLoS ONE, 2015, 10, e0120046.	1.1	10
92	EMX2 Is a Predictive Marker for Adjuvant Chemotherapy in Lung Squamous Cell Carcinomas. PLoS ONE, 2015, 10, e0132134.	1.1	18
93	Impact of the leucocyte immunoglobulin-like receptor A3 (<i>LILRA3</i>) on susceptibility and subphenotypes of systemic lupus erythematosus and Sjögren's syndrome. Annals of the Rheumatic Diseases, 2015, 74, 2070-2075.	0.5	30
94	<sc>APLAR</sc> rheumatoid arthritis treatment recommendations. International Journal of Rheumatic Diseases, 2015, 18, 685-713.	0.9	109
95	A Retrospective Study of Stage I to IIIa Lung Adenocarcinoma After Resection: What Is the Optimal Adjuvant Modality for Patients With an EGFR Mutation?. Clinical Lung Cancer, 2015, 16, e173-e181.	1.1	23
96	Is radical mediastinal lymphadenectomy necessary for elderly patients with clinical N-negative non-small-cell lung cancer? A single center matched-pair study. Journal of Surgical Research, 2015, 193, 435-441.	0.8	10
97	Retrospective study of surgery versus non-surgical management in limited-disease small cell lung cancer. Thoracic Cancer, 2014, 5, 405-410.	0.8	9
98	Simultaneous chemiluminescence detection of multiple tumor markers using bio-functionalized magnetic nanocomposites. , 2014, , .		1
99	Decreased maspin combined with elevated vascular endothelial growth factor <sc>C</sc> is associated with poor prognosis in non-small cell lung cancer. Thoracic Cancer, 2014, 5, 383-390.	0.8	5
100	Thoracoscopic Transclavicular Approach for a Large Thoracic Inlet Tumor. Annals of Thoracic Surgery, 2014, 98, e91-e93.	0.7	1
101	Does an extended mediastinal lymphadenectomy improve outcome after R0 resection in lung cancer?. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2014, 26, 183-91.	0.7	2
102	Retrospective study of surgical resection in the treatment of limited stage small cell lung cancer. Thoracic Cancer, 2013, 4, 395-399.	0.8	7